Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Post by duskwon Aug 01, 2012 12:55pm
228 Views
Post# 20173874

R&D investments

R&D investments

To elaborate on my prior comments regarding R&D investments - let's look at the Q2, 2008 revenue and margins and the prior years worth of R&D investments.

 

2006 R&D Total = $4.7 million

2007 R&D total = $5.2 million

2008 R&D total = $8.1 million

2009 R&D total = $8.9 million

2010 R&D total = $10.3 million

2011 R&D total = $11.5 million

2012 R&D total (est) = $12.8 million

 

Q2, 2008 revenue / GM was $23 and 52%. Prior TWO year investment in R&D was $9.9 million

Jump forward to 2012. Looking at the past TWO years of R&D ($21.5) million, HEM managed to DECREASE their revenue, and DECREASE their GM down to 43% all while more than doubling their R&D 'investment'.

 

Makes you wonder exactly how they are determinig where to spend their R&D dollars. The analyst today on the call had a great question regarding GM. It doesn't seem that the company has an active program or plan in place to improve GM on existing products. What exactly is all the R&D going towards then??

 

Not a great way to run a hardware company - but, oh wait, SK decided what Hemisphere GPS shouldn't really be a hardware company anymore. Now it's going to shift it's focus towards software! Hmmm... 

 

I think there is value in this company - but only as a combined entity with another player to grow their market share and scale. Obviously management saw this but for whatever reason killed the deal that was discussed Q2, 2011 (and cost them $800k). I bet looking back now that deal should have been done, eh? I bet it wasn't done since it didn't enrich management enough.

 

Bullboard Posts